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hippocampus dose was Dmax less than 17Gy without 
compromising the coverage of planning target volume (PTV) 
and other organs at risk were prioritized over hippocampal 
constraint. The mini-mental state examination (MMSE) and 
Seoul verbal learning test for total recall, delayed recall and 
recognition (SVLT-TR, DR, R) were performed at baseline and 
at 7 and 13 or 16 months after radiotherapy.  
 
Results: A total of 41 patients were accrued. Median age was 
48 years (range 26-76) and 51.2 % of the patients were male. 
Eighteen patients (43.9%) had WHO grade I or II tumor 
whereas 23 patients (56.1%) had grade III or IV tumor. Median 
volume of PTV was 192.8 cc (range 33.4-522.6) and median 
prescribed dose was 60Gy (range 46-66). Concurrent 
chemotherapy was given to 18 patients (43.9%). Median 
D100% and Dmax to the contralateral hippocampus were 
7.7Gy (range 0.6-24.8) and 16.6 Gy (range 3.56-60.4) 
respectively. Mean dose to contralateral hippocampus could 
be spared to less than 21 Gy in 39 patients with median value 
of 11.6 Gy (range 0.3-37.3) which was lower compared to 
previous documentation. Median value of maximal dose to 
lenses and eyeballs were 4.3 Gy (0.4-8.1) and 13.7 Gy (0.5-
46.6) respectively. At median follow up of 7.8 months (range 
0-14.8), median progression-free survival and overall survival 
were not reached. Cognitive function tests at 7 months were 
analyzable in 12 patients. For these patients, MMSE, SVLT-TR, 
SVLT-DR and SVLT-R at 7 months showed improved results 
compared to the baseline with 2.0% (95% CI, -0.8% to 4.7%), 
11.0% (95% CI, 3.3% to 18.8%), 20.1% (-5.5% to 45.8%) and -
0.6% (95% CI, -6.6% to 8.2%) increase respectively. No grade 4 
or 5 toxicity was reported.  
 
Conclusion: Hippocampus could be spared effectively in 
radiotherapy to primary brain tumors using VMAT. Despite 
limited follow up data, cognitive function tests of the 
patients showed promising results. Further follow up data 
would clarify the effect of hippocampal sparing on the 
cognitive function of the patients treated with radiotherapy 
for primary brain tumor.  
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Purpose or Objective: To analyze pre-treatment MRI- and 
18F-fluoroethylthyrosine-PET- (FET-PET) based target 
volumes and patterns of failure following radiotherapy (RT) 
with concurrent temozolomide (TMZ) for primary 
glioblastoma multiforme (GBM). 
 
Material and Methods: Thirty-four patients with primary GBM 
were treated using MRI based treatment volumes (GTVrm). 
Before treatment patients underwent FET PET/CT scans and 
biological tumor volume (GTVpet) were contoured but not 
used for target definition. Progression were defined 
according to RANO criteria. Tumor progression and pre-
treatment MRI and PET scans were co-registered to the 
radiation dose map. Failures were classified based on 
location of primary GTVs and dose delivered at the site of 
failure. We investigated volumetric size and uniformity of 
MRI- vs. FET-PET/CT-derived GTVs and progression patterns 
assessed by means of FET PET/CT and MRI. 
 
Results: FET-PET based GTVs measured 10 minutes after 
radionuclide injection (a.r.i.) (median 37.3 cm3) were larger 
than GTVs measured 60 minutes a.r.i. (median 27,7 cm3). 
GTVpet were significantly larger than corresponding MRI 
based GTVs (median 19,3 cm3). The congruence of MRI and 
FET signals for the identification of glioblastoma GTVs is poor 
with mean uniformity index of 0.4 (p=0,0). 74% of failures 
were located inside primary GTVpet. 68% of failures occured 
within the 95% isodose line, and 9% within 60 Gy isodose. 
 
Conclusion: The size and geometrical location of GTVs 
differed in a majority of patients. The volume of GTVpet 
depends on time a.r.i. Tumor progression were mostly inside 
FET-PET volumes. FET PET better defined failure site then 
MRI. Finally dose inhomogenity inside GTVpet and GTVrm and 
favourable tumor control within 60Gy isodose advocates 
further studies with PET-MR based high-dose radiation 
therapy of GBM. 
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Purpose or Objective: Temozolomide (TMZ) based 
chemoradiotherapy defines the current gold standard for the 
treatment of newly diagnosed glioblastoma. Data regarding 
the influence of TMZ dose density during chemoradiotherapy 
are currently not available. We retrospectively compared 
outcomes in patients receiving no TMZ, patients receiving 
TMZ during radiotherapy on radiotherapy days only (5/7) and 
patients receiving TMZ constantly 7 days a week (7//7).  
 
Material and Methods:  
From 2002 to 2012 a total of 432 patients with newly 
diagnosed glioblastoma received radiotherapy in our 
department. 118 patients had radiotherapy alone, 210 had 
chemoradiotherapy with temozolomide (75 mg/m²) daily (7/7 
days a week) and 104 chemoradiotherapy with temozolomide 
only on radiotherapy days (5/7 days a week, Monday till 
Friday). Radiotherapy was applied in 30 fractions to a total 
dose of 60 Gy. 
 
Results: Median survival after radiotherapy alone was 9.1 
months, compared to 12.6 months with temozolomide 5/7 
and to 15.7 months with temozolomide 7/7. The 1 year 
survival was 33% in the radiotherapy only group, 52% in the 
5/7 group and 64% in the 7/7 group. Kaplan Meier analysis 
showed a significant improvement of temozolomide 7/7 vs. 
5/7 (p=0.01 by the log-rank test), while temozolomide 5/7 
was still superior to no temozolomide at all (p=0.02). 
 
Conclusion: Our results confirm the findings of the 
EORTC/NCIC-trial by Stupp et al., establishing the daily 
temozolomide chemoradiotherapy as standard therapy for 
glioblastoma. Also a reduced temozolomide scheme can at 
first prolong the survival of glioblastoma patients, but not as 
much as the daily application. 
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Purpose or Objective: We aimed to identify subventricular 
zone (SVZ)-related prognostic factors of survival and patterns 
of relapse among patients with glioblastoma. 
 
Material and Methods: Forty-three patients with primary 
diagnosed glioblastoma treated in our Cancer Center 
between 2006 and 2010 were identified. All patients received 
surgical resection, followed by temozolomide-based 
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chemoradiation (60 Gy, 2 Gy per fraction). Ipsilateral (iSVZ), 
contralateral (cSVZ), and bilateral (bSVZ) SVZs were 
retrospectively segmented following two delineation 
methods: with (TH+) and without (TH-) temporal horns. Dose-
volume histograms were retrospectively generated on the 
original plans. Progression was defined according to the RANO 
criteria. Multivariate analysis using the Cox proportional 
hazards model including significant covariates in univariate 
analysis was assessed to examine the relationship between 
prognostic factors and time to progression (TTP). 
 
Results: Median age was 59 years (range: 25-85). Median 
follow-up, OS and TTP were 52.8 months (95% CI 43.4-61.1), 
26.2 months (95% CI 20.3-34.2) and 6.4 months (95% CI 4.4-
9.3), respectively. On univariate analysis, initial contact to 
SVZ was a poor prognostic factor for OS (20.5 vs 56.4 months, 
p = 0.011) and TTP (4.6 vs 12.9 months, p = 0.002). With TH- 
method, patients receiving mean dose to bSVZ greater than 
40 Gy had a significantly improved TTP, as well as patients 
whose V20 Gy to bSVZ was greater than 84% (17.7 months vs 
5.2 months, p = 0.017). On multivariate analysis, initial 
contact to SVZ and V20 Gy to bSVZ lesser than 84% remained 
poor prognostic factors for TTP (HR = 3.07, p = 0.012 and HR 
2.67, p = 0.047, respectively). 
 
Conclusion: Our results suggest that contact to SVZ, as well 
as insufficient bSVZ coverage such as a V20 Gy lower than 
84%, are independent poor prognostic factors for TTP. 
Therefore, targeting SVZ is of crucial interest for optimizing 
glioblastoma treatment. 
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Purpose or Objective: The accuracy in contouring the target 
is one of the key factors for the success of stereotactic 
radiosurgery (SRS). This is particularly important when 
delivering one large fraction of radiation with small or no 
margins, since the consequence of not defining the correct 
clinical target volume can be that intended treatment results 
are not achieved. Furthermore, accurate contouring of the 
relevant Organs-at-Risk (OARs) is essential to minimize any 
normal tissue toxicity. The aim of this study was to analyze 
and quantify the variability of target and OAR contouring for 
two lesions in the brain. 
 
Material and Methods: A multicenter analysis of the 
variability in contouring the target and the OARs for two 
typical cases of brain disorders, a cavernous sinus 
meningioma and a vestibular schwannoma was performed. 
Twelve Gamma Knife centers from around the world have 
participated in the study by contouring the targets and the 
OARs. The resulting treatment plans were analyzed with 
respect to the agreement in target and OARs contouring.  
The 50 %-agreement volume, AV50, and the common volume, 
AV100, together with the encompassing volume, AV100/N, 
were determined based on a binary analysis method. A novel 
metric for the variability in delineation defined as the 
Agreement-Volume-Index was introduced and additionally 
calculated. The variability of the contoured structures was 
also analyzed with respect to the position of their centers of 
mass (COMs). 
 
Results: Substantial disagreement in target delineation was 
observed with an Agreement-Volume-Index of 0.22 for the 
meningioma case and 0.50 for the vestibular schwannoma 
case, respectively. Very high disagreement was also observed 
for the delineation as OARs of the optic apparatus and 
cochlea with an Agreement-Volume-Index ranging from 0 to 
0.13. The disagreement was observed with respect to the 
shape, size and position of the contoured volumes. The 
resulting disagreement in target volumes was highest for the 
meningioma (range 5.29-7.80 cm3) while a lower disparity 
was observed for the schwannoma (range 3.56-4.48 cm3). 
The majority of structures analyzed displayed the highest 
disagreement of the COM in longitudinal direction. An 
illustration of the displacement of the COMs together with 
the common volume and encompassing volume is shown in 
Figure 1 for the cavernous sinus meningioma case. 
 
Figure 1. Illustration of the displacement of the COMs (red 
dots) together with the common volume (blue) and 
encompassing volume (green) for the cavernous sinus 
meningioma case. 
 
Conclusion: Differences in target and OARs contouring 
expressed using different parameters, including a novel 
metric, emphasize the importance of further investigating 
and standardizing the contouring in SRS. Therefore, clinically 
significant differences in target and OARs delineation might 
lead to the need of better contouring tools, education and 
standardized protocols in SRS. 
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Purpose or Objective: The latency, overall extent, and rate, 
of distant brain failure for non-small cell lung cancer patients 
undergoing SRS for brain metastases is not well 
characterized. We evaluated the impact of multiple pre-
treatment parameters including age, KPS, extracranial 
disease status (ECD), initial number of metastases, initial 
aggregate tumor volume, and histological/molecular 
subtypes, on distant brain failure. We also evaluated the 
impact of WBRT performed before, combined with, or after 
SRS.  
 
Material and Methods: The retrospective study population 
included 118 NSCLC patients with brain metastases treated 
with SRS between 11/2008 and 01/2014. The distant brain 
metastasis-free survival (DBMFS) was defined as latency in 
months from initial SRS to first subsequent radiographic 
evidence of new brain metastasis. The extent of overall 
distant brain failure (ODBF) was defined as the total number 
of new metastases that developed following initial SRS 
treatment. The distant brain failure rate (DBFR) was defined 
as the ODBF/RFI where RFI was defined as the maximum 
radiographic follow-up interval in months. Kaplan Meir 
analysis was used to evaluate DBMFS and Log Rank test was 
used to determine the significance (p-value <0.05 was 
considered significant). For ODBF and DBFR, Independent 
